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Background: Clinically nonfunctional pituitary adenomas (NFPAs) without any clinical elevation of hormone and
with a difficulty in its early-stage diagnosis are highly heterogeneous with different hormone expressions in NFPA
tissues, including luteinizing hormone (LH)-positive, follicle-stimulating hormone (FSH)-positive, LH/FSH-positive, and
negative (NF). Elucidation of molecular mechanisms and discovery of biomarkers common and specific to those
different subtypes of NFPAs will benefit NFPA patients in early-stage diagnosis and individualized treatment.
Methods: Two-dimensional gel electrophoresis (2DGE) and PDQuest image analyses were used to compare
proteomes of different NFPA subtypes (NF-, LH-, FSH-, and LH/FSH-positive) relative to control pituitaries (Con).
Differentially expressed proteins (DEPs) were characterized with mass spectrometry (MS). Each set of DEPs in four
NFPA subtypes was evaluated with overlap analysis and signaling pathway network analysis with comparison to
determine any DEP and pathway network that are common and specific to each NFPA subtype.
Results: A total of 93 differential protein-spots were determined with comparison of each NFPA type (NF-, LH-, FSH-, and
LH/FSH-positive) versus control pituitaries. A total of 76 protein-spots were MS-identified (59 DEPs in NF vs. Con;
65 DEPs in LH vs. Con; 63 DEPs in FSH vs. Con; and 55 DEPs in LH/FSH vs. Con). A set of DEPs and pathway network
data were common and specific to each NFPA subtype. Four important common pathway systems included
MAPK-signaling abnormality, oxidative stress, mitochondrial dysfunction, and cell-cycle dysregulation. However, these
pathway systems were, in fact, different among four NFPA subtypes with different protein-expression levels of most of
nodes, different protein profiles, and different pathway network profiles.
Conclusions: These result data demonstrate that common and specific DEPs and pathway networks exist in four NFPA
subtypes, and clarify proteome heterogeneity of four NFPA subtypes. Those findings will help to elucidate molecular
mechanisms of NFPAs, and discover protein biomarkers to effectively manage NFPA patients towards personalized
medicine.
Keywords: Nonfunctional pituitary adenoma, Proteome, Heterogeneity, Two-dimensional gel electrophoresis, Mass
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Clinically nonfunctional pituitary adenomas (NFPAs) are
a very challenging clinical problem in pituitary tumor
patients relative to functional pituitary adenomas (FPAs)
because an NFPA does not have any elevation of the cor-
responding hormone [1,2]. Thus, an NFPA commonly* Correspondence: yjzhan2011@gmail.com
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unless otherwise stated.cannot be diagnosed until presentation of visual injuries
and compression symptoms of neighboring tissues, when
the tumor has progressed to the middle/late stage. An
opportunity is lost for early-stage treatment, and central
endocrine regulatory roles of the pituitary, are both lost.
The use of proteomics to elucidate molecular mecha-
nisms and discover tumor-related NFPA biomarkers is
our long-term goal. Extensive proteomics studies of
pituitary adenomas have been carried out in our, and
other, research groups [3-10], including protein expres-
sion profiles [11-14], differentially expressed proteins
(DEPs) [15,16], protein post-translational modificationshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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phosphorylation [20,21], hormone isoforms [22], protein
molecular pathway networks [16,23] from comparative
proteomics and systems biology analyses between NFPA
versus control tissues [15,23] and between invasive versus
noninvasive NFPAs [16], and serum protein biomarkers in
pituitary adenomas [6-8]. Moreover, a protein antibody
array (n = 1,005 proteins) based on pituitary adenoma
proteomics data was used to analyze human pituitary ad-
enomas and identify a DEP profile [24]. A clinical prote-
omic method that was used to accurately stratify pituitary
adenomas was based on multiplex immunoassays of pep-
tide hormones extracted from formalin-fixed and paraffin-
embedded tissue [9,10]. Laser capture microdissection
(LCM) coupled with proteomics was used to accurately
identify the proteomic variation of an adenoma relative to
control pituitary [25-27]. Proteomics data-based systems
pathway network analysis revealed four important signal
pathway network variations in NFPA pathophysiological
processes, including mitochondrial dysfunction, oxidative
stress, cell-cycle dysregulation, and MAPK-signaling sys-
tem abnormality [23]. However, those proteomic studies
did not consider NFPA heterogeneity. In fact, NFPA is
highly heterogeneous – it has different types of cell origins
and hormones expressed in tumor tissues, including silent
somatotroph (growth hormone GH-positive; 3%), silent cor-
ticotroph (adrenocorticotropic hormone ACTH-positive;
8%), oncocytoma (no hormone expression; 6%), null cell
(no hormone expression; 17%), and gonadotroph (intact
follicle-stimulating hormone/luteinizing hormone FSH/
LH or subunits; 40-79%) that was subclassified as LH-
positive, FSH-positive, and LH/FSH-positive NFPAs [15].
Studies demonstrate that the silent hormone expression in
NFPA tissue is associated with tumor behaviors such as
invasion [28,29]. Therefore, it is essential to investigate
proteomic variations in different NFPA subtypes for an
in-depth and accurate understanding of common and spe-
cific NPFA mechanisms and discovery of reliable bio-
markers toward individualized medical practice. Thus, we
emphasize the scientific importance to investigate the he-
terogeneity of NPFA proteomes. A comparative analysis of
proteomes in different NFPA subtypes (NF-, LH-, FSH-,
and LH/FSH-positive) relative to normal control pitui-
taries described here revealed variations in protein expres-
sions and pathway networks among four NFPA subtypes,
and revealed the common and specific molecular me-
chanisms and protein biomarkers for different NFPA
subtypes.
Two-dimensional gel electrophoresis (2DGE)-based com-
parative proteomics [30,31] is a classical and effective ap-
proach to quantify each DEP in different NFPA subtypes
(NF-, LH-, FSH-, and LH/FSH-positive) versus normal
control pituitaries. The linear dynamic separation range,
spatial and quantitative reproducibility, and experimentalconditions of 2DGE-based proteomics were optimized in
our previous studies [32,33]. Isoelectric focusing (IEF) has
a high reproducibility due to use of highly reproducible
commercial immobilized pH gradient (IPG) strip. The ver-
tical multi-gel sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) system, which has a higher
reproducibility and wider linear dynamic range, was used
to array the proteome of each NFPA subtype and control
pituitary. PDQuest 2D image software was used to quan-
tify DEPs of each NFPA subtype relative to controls.
Matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF)-based peptide mass fingerprint (PMF),
liquid chromatography (LC)-electropray ionization (ESI)-
based tandem mass spectrometry (MS/MS), and human
Swiss-Prot protein databases were used to identify each
DEP. Systems biology-based pathway network analysis
was used to reveal variations of protein molecular net-
works among different NFPA subtypes. Thus, this study is
the first to reveal variations in proteomes and molecular
networks among four NFPA subtypes (NF-, LH-, FSH-,
LH/FSH-positive NFPAs), and the heterogeneity of NFPA
proteomes. Scheme 1 shows the overall experimental flow-
chart that was used to identify variations of proteomes and
molecular networks among four NFPA subtypes.
Results
2DGE pattern and DEP profile of each NFPA subtype
relative to control pituitaries
2DGE-based comparative proteomics was used to ana-
lyze proteome variations from controls (n = 8; 3 to 5 gel
images per sample) versus each NFPA type, including
NF- (n = 3; 3 gel images per sample), LH- (n = 3; 3 gel
images per sample), FSH- (n = 3; 3 gel images per sam-
ple), and LH/FSH- (n = 3; 3 gel images per sample) ad-
enoma tissues. Each sample was 2DGE-analyzed three to
five times to provide a triplicate, high-quality 2DGE gel
image for each sample. Figure 1 shows the digitized
master 2D gel image. Ca. 1,000 protein-spots were de-
tected in each gel image with PDQuest 2D gel-image
analysis with high-resolution, high-spatial reproducibility
in the IEF and SDS-PAGE directions, and high reprodu-
cibility for triplicate 2D gel images of each sample.
2DGE protein-spots mainly distributed within pH 4–9
and relative mass (Mr) 15–150 kDa. For each sample,
the average between-gel matched percentage ranged
from 85% to 99% for control pituitaries and 81% to 90%
for NFPAs; the positional deviation of matched spots
among triplicate 2D gel images was 2.13 ± 0.79 mm in
the IEF direction and 1.82 ± 0.68 mm in the SDS-PAGE
direction; and the correlation coefficient (r) of nor-
malized spot-volumes for between-gel matched spots
was > 0.76 with a range of 0.76-0.92. The high-spatial re-
producibility and quantitative reproducibility resulted
from the same experimental condition maintained for
2DGE
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Scheme 1 Overall experimental flow-chart used to analyze the proteomic variations among different NFPA subtypes (NF-, LH-, FSH-,
and LH/FSH-). NFPA, nonfunctional pituitary adenoma; 2DGE, two-dimensional gel electrophoresis; DEP, differentially expressed proteins; MS,
mass spectrometry; and IPA, Ingenuity Pathway Analysis.
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SDS-PAGE, visualization, gel digitalization, and image
analysis. That reproducibility provided an accurate com-
parison between each NFPA subtype and controls.
A total of 93 differential protein-spots was determined
with comparison of each NFPA subtype (NF-, LH-, FSH-,
and LH/FSH-) versus control pituitaries with a cut-off
value of >3-fold and a statistically significant difference
(p < 0.001). Figure 2 shows a representative DEP-spot
(Spot-1311) among different NFPA subtypes (n = 9 gel
images for each type of NFPAs) versus controls (n = 30 gel
images) (Figure 2A) and a quantitative comparison of nor-
malized spot-volumes between each NFPA subtype versus
controls (p < 0.001) (Figure 2B). Each differential protein-
spot was labeled in the master gel image (Figure 1). Each
differential protein-spot was excised, and proteins were
subjected to in-gel digestion with trypsin, followed by MS
analysis, including MALDI-TOF PMF and LC-ESI-MS/
MS. A total of 72 differential protein-spots that contained
DEPs were MS-identified from those 93 differential
protein-spots. Four spots (SSP No. 1017, 1103, 2310, and
2419 in Table 1 and Figure 3) of 72 MS-identified spots
contained two proteins; therefore, 72 spots represent 76
protein-spots. Among those 76 protein-spots, 59 DEPs(44 downregulated and 15 upregulated) were identified in
NF-NFPA relative to controls, 65 DEPs (45 downregulated
and 20 upregulated) in LH-NFPA, 63 DEPs (43 down-
regulated and 20 upregulated) in FSH-NFPA, and 55 DEPs
(41 downregulated and 14 upregulated) in LH/FSH-NFPA.
Those DEPs are summarized in Table 1, which contains
the SSP number that corresponds to the number labeled
in Figure 1, protein name, Swiss-Prot accession number,
and fold-value in each NFPA subtype versus controls.
Comparative analysis of DEP profiles derived from four
NFPA subtypes relative to controls
An overlapping analysis (Figure 3) among 59 DEPs in NF-
NFPA, 65 DEPs in LH-NFPA, 63 DEPs in FSH-NFPA, and
55 DEPs in LH/FSH-NFPA relative to controls (Table 1)
revealed that 44 DEPs were common to four NFPA sub-
types (NF-, LH-, FSH-, and LH/FSH-). Those 44 common
DEP-spots among four NFPA subtypes (NF-, LH-, FSH-,
and LH/FSH-) include ten upregulated and 34 downregu-
lated DEPs. Those ten common upreguated DEPs were F-
actin capping protein beta unit, splice isoform 2 of F-actin
capping protein beta unit, zinc finger protein 266, G(O)-
protein alpha subunit 1, G(O)-protein alpha subunit 2,
aldose reductase, tryptophan 5-hydroxylase, glutathione
Figure 1 Two-dimensional gel electrophoresis reference map from a human pituitary control proteome labeled with 72 differential
spots among different NFPA subtypes (NF-, LH-, FSH-, and LH/FSH-). The isoelectric focusing (IEF) was carried out with an 18-cm IPG strip
(pH 3–10 NL), and a vertical SDS-PAGE with a 12% polyacrylamide gel.
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cytoplasmic, and peroxisomal acyl-coenzyme A thioester
hydrolase 2A. The 34 common down-regulated DEPs
were somatotropin chain 1, splice isoform 2 of somatotro-
pin precursor, growth hormone variant precursor, prolac-
tin chain 1, splice isoform IL15-S21AA of interleukin-15
precursor, factor X light chain, cytokeratin 16, alpha
crystalline C chain, 14-3-3 protein tau, secretagogin,
Mu-crystallin homolog, MIMECAN chain 1, tissue trans-
glutaminase, ATP binding protein associated with cell
differentiation, N6-adenosine-methyltransferase 70 kDa
subunit, hemoglobin beta unit variant, hemoglobin beta-2
chain, and insulin-like growth factor binding. Among
them, 16 common DEP-spots contained somatotropin
and its isoforms with different pI and Mr, and four com-
mon DEPs contained prolactin and its isoforms with
different pI and Mr. Those common DEPs hint at the
common molecular mechanisms and signaling pathways
involved in four NFPA subtypes.
Four DEPs (SSP 2101, 4215, 2624, and 1608) were
common to only three NFPA subtypes (NF-, LH-, and
LH/FSH-), including three down-regulated proteins
(somatotropin chain 1, prolactin precursor, and dipeptidyl-
peptidase II) and one up-regulated protein (mitochondrial
ATP synthase beta chain). Three DEP-spots (SSP 4216,8102, and 1105) were common to only three NFPA
subtypes (LH-, FSH-, and LH/FSH-), including two down-
regulated proteins (prolactin chain 1, and phospholipid
hydroperoxide glutathione peroxidase) and one up-
regulated protein (lactoylglutathione lyase). Two DEP-
spots (SSP 2001, and 7106) were common to only three
NFPA subtypes (NF-, FSH-, and LH/FSH-), including one
down-regulated protein (CD59 glycoprotein) and one
up-regulated protein (40 kDa peptidyl-prolyl cis-trans
isomerase).
Eight DEPs (SSP 4921, 8208, 0118, 1107, 2008, 3013,
4012, and 6115) were common to only two NFPA sub-
types (LH-, and FSH-), including two down-regulated pro-
teins (collagen alpha 2 VI chain, and Ig kappa chain V-III
region SIE) and six up-regulated proteins (lactoylglu-
tathione lyase, NADH-ubiquinone oxidoreductase 23 kDa,
enhancer of rudimentary homolog, acyl-CoA-binding pro-
tein, cytochrome c oxidase polypeptide VIb, and neuronal
protein NP25). Four DEPs (SSP 0812, 5003, 1610, and
1705) were common to only two NFPA subtypes (NF-,
and LH-), including two down-regulated proteins (tumor
rejection antigen 1, and hemoglobin beta-2 chain) and
two up-regulated proteins (vimentin, and Rab GDP dis-
sociation). Three DEPs (SSP 2303, 3210, and 5617) were
common to only two NFPA subtypes (NF-, and FSH-),
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Figure 2 A representative differential spot among different NFPA subtypes versus control pituitaries (Spot-1311). Control means control
pituitaries; LH means LH-positive NFPA; FSH means FSH-positive NFPA; LH/FSH means LH/FSH-positive NFPA; and NF means NFPA with negative
hormone expression. A statistically significant difference existed between each type of NFPAs versus control pituitaries (p < 0.001). A. The 2DGE
images (Spot-1311) among four NFPA subtypes. B. The normalized spot-volume (Spot-1311) among four NFPA subtypes.
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protein phosphatase 2A - 55 kDa regulatory subunit B
alpha isoform, and heat shock protein 27) and one up-
regulated protein (proto-oncogene tyrosine-protein kinase
FYN). One DEP-spot (SSP 7016) was common to only
two NFPA subtypes (FSH-, and LH/FSH-), which was a
down-regulated protein (hemoglobin alpha-2 chain).
Two DEPs (SSP 1012, and 1117) were specific to NF-
NFPAs, which were two down-regulated proteins (splice
isoform 3 of alpha-s1 casein precursor, and apolipopro-
tein A-I). Two DEPs (SSP 2311, and 3222) were specific
to FSH-NFPAs, including one down-regulated protein
(L-Myc-1 protooncogene protein) and one up-regulated
protein (endoplasmic reticulum protein ERP29). OneDEP-spot (SSP 1017) was specific to LH-NFPAs, which
contained two down-regulated proteins (somatotropin, and
splice isoform 2 of somatotropin precursor). One DEP-spot
(SSP 7519) was specific to LH/FSH-NFPAs, which was one
up-regulated protein (matrix metalloproteinase-19).
Variations in signaling pathway networks among four
NFPA subtypes
Each protein functions in an organized, systematic, and
dynamic pathway network system. The Ingenuity Pathway
Analysis (IPA) program was used to clarify pathway net-
works that involve each DEP and to address potential bio-
logical functions of those DEPs in each NFPA subtype
(NF-, LH-, FSH-, and LH/FSH-). DEPs were analyzed with
Table 1 Differentially expressed proteins in different subtypes of clinically nonfunctional pituitary adenomas versus controls
SSP no. Protein name Swiss-Prot no. NF-NFPA LH-NFPA FSH-NFPA LH/FSH-NFPA
1011 Chain 1: somatotropin P01241 180.6(−) 44.1(−) 82.6(−) 90.5(−)
1017 Chain 1: somatotropin P01241 13.3(−)
1017 Splice isoform 2 of somatotropin precursor P01241 isoform 13.3(−)
1102 Chain 1: somatotropin P01241 20.2(−) 6.5(−) 9.1(−) 9.3(−)
1103 Somatotropin precursor P01241 14.1(−) 2.9(−) 3.3(−) 5.8(−)
1103 Growth hormone variant precursor P01242 14.1(−) 2.9(−) 3.3(−) 5.8(−)
1109 Chain 1: somatotropin P01241 isoform (−−) 128.3(−) 69.4(−) (−−)
1121 Chain 1: somatotropin P01241 6.2(−) 2.8(−) 2.7(−) 3.3(−)
1122 Chain 1: somatotropin P01241 48.1(−) (−−) 7.5(−) 8.1(−)
1123 Chain 1: somatotropin P01241 17.3(−) 4.4(−) 6.4(−) (−−)
2002 Splice isoform 2 of somatotropin precursor P01241 isoform 9.7(−) 3.9(−) 3.2(−) 5.4(−)
2003 Chain 1: somatotropin P01241 (−−) 88.8(−) 25.0(−) (−−)
2101 Chain 1: somatotropin P01241 27.8(−) (−−) 17.4(−)
2106 Chain 1: somatotropin P01241 (−−) 9.4(−) 2.2(−) 51.2(−)
2115 Chain 1: somatotropin P01241 (−−) 32.1(−) (−−) (−−)
2128 Chain 1: somatotropin P01241 (−−) 82.1(−) 67.4(−) 478.6(−)
2129 Chain 1: somatotropin P01241 13.4(−) 6.7(−) 4.3(−) 5.5(−)
3004 Chain 1: somatotropin P01241 42.0(−) 37.0(−) 21.2(−) 13.6(−)
3107 Chain 1: somatotropin P01241 30.5(−) (−−) 19.1(−) 34.9(−)
4106 Chain 1: prolactin P01236 8.3(−) 12.6(−) 46.2(−) 99.9(−)
4215 Prolactin precursor P01236 4.9(−) 4.1(−) 3.8(−)
4216 Chain 1: prolactin P01236 26.2(−) 14.6(−) 12.3(−)
5114 Chain 1: prolactin P01236 (−−) 20.1(−) 17.6(−) 19.0(−)
6109 Chain 1: prolactin P01236 (−−) 36.7(−) (−−) 19.7(−)
6119 Chain 1: prolactin P01236 (−−) 33.6(−) 11.3(−) 32.6(−)
0020 Splice isoform IL15-S21AA of interleukin-15 precursor P40933-2 isoform (−−) (−−) 1.6(−) 2.7(−)
0029 Chain 1: Factor X light chain P00742 (−−) (−−) 29.3(−) 38.9(−)
0511 Cytokeratin 16 P08779 28.8(−) 2.1(−) 15.7(−) 18.5(−)
0112 Alpha crystallin C chain Q9UJY1 (−−) 2.3(−) (−−) (−−)
0812 Chain 1: Endoplasmin (Tumor rejection antigen 1) P14625 11.0(−) 4.4(−)
1010 14-3-3 protein tau P27348 (−−) (−−) 6.4(−) 15.5(−)
1012 Splice isoform 3 of alpha-s1 casein precursor P47710-3 isoform 17.8(−)














Table 1 Differentially expressed proteins in different subtypes of clinically nonfunctional pituitary adenomas versus controls (Continued)
1311 Secretagogin O76038 6.6(−) 2.1(−) 2.3(−) 3.4(−)
1402 Mu-crystallin homolog Q14894 16.3(−) 4.6(−) 2.4(−) 4.6(−)
1404 Chain 1: MIMECAN P20774 38.0(−) 6.1(−) 9.1(−) 16.2(−)
1806 Tissue transglutaminase P21980 (−−) 17.1(−) (−−) (−−)
2001 CD59 glycoprotein P13987 9.5(−) 2.4(−) 4.1(−)
2303 Serine/threonine protein phosphatase 2A, 55 kDa regulatory subunit B, alpha isoform Q00007 8.2(−) 2.6(−)
2311 L-Myc-1 protooncogene protein P12524 7.4(−)
2624 Chain 1: dipeptidyl-peptidase II Q9UHL4 9.3(−) 2.5(−) 5.3(−)
3210 Heat shock protein 27 P04792 2.4(−) 4.9(−)
4001 ATP binding protein associated with cell differentiation O14530 11.4(−) 2.3(−) 2.7(−) 4.4(−)
4921 Chain 1: collagen alpha 2 (VI) chain P12110 5.3(−) 14.7(−)
5003 Hemoglobin beta-2 chain P18988 3.1(−) 2.1(−)
6103 N6-adenosine-methyltransferase 70 kDa subunit Q86U44 6.2(−) 6.5(−) (−−) 8.3(−)
7004 Hemoglobin beta unit variant gi1066765 (−−) 176.7(−) (−−) (−−)
7014 Hemoglobin beta-2 chain P18988 (−−) 29.4(−) 28.9(−) 99.4(−)
7016 Hemoglobin alpha-2 chain P01968 20.2(−) 13.3(−)
8101 Chain 1: insulin-like growth factor binding P24592 (−−) 2.9(−) 20.9(−) 5.0(−)
8102 Chain 1: phospholipid hydroperoxide glutathione peroxidase P36969 3.9(−) 2.1(−) 14.4(−)
8208 Ig kappa chain V-III region SIE P01620 4.1(−) 32.5(−)
0118 Lactoylglutathione lyase Q04760 9.1(+) 10.2(+)
1105 Lactoylglutathione lyase Q04760 6.6(+) 8.3(+) 5.1(+)
1107 NADH-ubiquinone oxidoreductase 23 kDa O00217 4.9(+) 5.2(+)
1608 ATP synthase beta chain, mitochondrial precursor P06576 5.0(+) 3.1(+) 2.8(+)
1610 Vimentin P08670 5.5(+) 2.6(+)
1705 Rab GDP dissociation inhibitor alpha P31150 9.4(+) 5.8(+)
2008 Enhancer of rudimentary homolog Q14259 5.0(+) 3.7(+)
2310 F-actin capping protein beta subunit P47756 2.7(+) 2.2(+) 6.5(+) 3.0(+)
2310 Splice isoform 2 of F-actin capping protein beta subunit P47756-2 isoform 2.7(+) 2.2(+) 6.5(+) 3.0(+)
2416 Zinc finger protein 266 Q14584 3.4(+) 2.4(+) 7.3(+) 2.8(+)
2419 Guanine nucleoide-binding protein G(O), alpha subunit 1 P09471 7.3(+) 2.1(+) 9.1(+) 9.5(+)
2419 Guanine nucleotide-binding protein G(O), alpha subunit 2 P29777 7.3(+) 2.1(+) 9.1(+) 9.5(+)
3013 Acyl-CoA-binding protein P07108 2.7(+) 4.3(+)














Table 1 Differentially expressed proteins in different subtypes of clinically nonfunctional pituitary adenomas versus controls (Continued)
4012 Cytochrome c oxidase polypeptide VIb P14854 4.4(+) 8.7(+)
4313 Aldose reductase P15121 5.7(+) 9.6(+) 14.6(+) 8.1(+)
4616 Tryptophan 5-hydroxylase (Neuronal tryptophan hydroxylase) Q8IWU9 10.6(+) 2.1(+) 7.8(+) 8.3(+)
5207 Glutathione S-transferase Mu-2 P28161 2.5(+) 2.8(+) 4.2(+) 2.9(+)
5617 Proto-oncogene tyrosine-protein kinase FYN P06241 2.8(+) 3.9(+)
6115 Neuronal protein NP25 Q9UI15 4.9(+) 4.6(+)
6508 Isocitrate dehydrogenase [NADP] cytoplasmic O75874 6.1(+) 6.7(+) 8.7(+) 4.4(+)
7503 Peroxisomal acyl-coenzyme A thioester hydrolase 2a P49753 2.8(+) 2.0(+) 2.2(+) 2.5(+)
7519 Chain 1: matrix metalloproteinase-19 Q99542 3.1(+)
7106 40 kDa peptidyl-prolyl cis-trans isomerase Q08752 4.3(+) 5.0(+) 5.1(+)
LH-NFPA =NFPA that expressed leuteinizing hormone, or lutropin; FSH-NFPA =NFPA that expressed follicle-stimulating hormone, or follitropin; LH/FSH-NFPA =NFPA that expressed both follicle-stimulating
hormone and leuteinizing hormone; NF-NFPA =NFPA that had negative immunohistochemical stains for ACTH, FSH, GH, LH, prolactin, and TSH. Each adenoma was graded blindly by a neuropathologist from 0–4 for intensity of






















Figure 3 Overlap analysis of differentially expressed proteins among four NFPA subtypes (NF-, LH-, FSH-, and LH/FSH-). Each number in
this figure is corresponded to the SSP number in the Table 1. Those duplicated SSP Numbers in the Table 1 are re-labeled in this figure as following:
1017(1) = Chain 1, somatotropin; 1017(2) = Splice isoform 2 of somatotropin precursor; 1103(1) = Somatotropin precursor; 1103(2) = Growth hormone
variant precursor; 2310(1) = F-actin capping protein beta subunit; 2310(2) = Splice isoform 2 of F-actin capping protein beta subunit; 2419(1) = Guanine
nucleoide-binding protein G(O), alpha subunit 1; and 2419(2) = Guanine nucleotide-binding protein G(O), alpha subunit 2. The red color number refers
to an upregulated protein. The black color number refers to a downregulated protein. The label (*) means those DEP-spots are common to only two
groups of LH- and FSH-NFPA, not to NF-NFPA.
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pathways, disease biological events, and biological toxicity
events and to reveal variations in signaling pathway net-
works to provide pathway networks, canonical pathways,
disease biological events, and biological toxicity events
that were common or specific to each NFPA subtype.
Differences in pathway networks
For NF-NFPAs, pathway network analysis of 59 DEPs in
NF-NFPAs identified three statistically significant pathway
networks that involve NF-NFPA-related DEPs (Figure 4A).
Those nodes in the top-half of Figure 4A correspond to
molecules (genes; proteins) summarized in the bottom-
half of Figure 4A. NF-network 1 functions in cell-to-cell
signaling and interaction, hematological system deve-
lopment and function, and immune cell tracking; and in-
cludes 35 nodes (genes; proteins). Among those 35 nodes,
18 DEPs (51% of total nodes) were MS-identified. ERK1/2,
PRL, APOA1, TGF beta, LDL, NOS, IL12 complex,
HSPB1, and YWHAQ play key roles in this network.
NF-network 2 functions in cardiovascular systemdevelopment and function, organism development, and
nervous system development and function; and includes
35 nodes (genes; proteins). Among those 35 nodes, nine
DEPs (26% of total nodes) were MS-identified. ERK, GH1,
PKA, RAS, Akt, VEGF, MAPK, FYN, p85 (pik3r), PI3K
complex, and insulin play key roles in this network. NF-
network 3 functions in auditory disease, development dis-
order, and endocrine system disorders; and includes 35
nodes (genes; proteins). Among those 35 nodes, eight
DEPs (23% of total nodes) were MS-identified. UBC,
FBXO32, P38 MAPK, NFkB complex, PI3K complex, and
PKC play key roles in this network.
For LH-NFPAs, pathway network analysis of 65 DEPs
in LH-NFPAs identified three statistically significant
pathway networks that involve LH-NFPA-related DEPs
(Figure 4B). Those nodes in the top-half of Figure 4B
corresponded to molecules (genes; proteins) summarized
in the bottom-half of Figure 4B. LH-network 1 functions
in cardiovascular system development and function, or-
ganism development, and cancer; and includes 35 nodes




Top Diseases and Functions
1 14-3-3, AKR1B1, Alp, APOA1, ATP5B, caspase, CD59, 
cytochrome C, ERK1/2, F10, GNAO1, Growth hormone, HDL, HSP, 
HSP90B1, HSPB1, HSPB8, Igfbp, IGFBP6, IL15, IL12 (complex), 
Immunoglobulin, KRT16, LDL, Nos, OGN, PPID, PPP2R2A, PRL, 
Rock, STAT5a/b, Tgf beta, TPH2, Ubiquitin, YWHAQ
42 35 18 Cell-To-Cell Signaling and 
Interaction, Hematological 
System Development and 
Function, Immune Cell 
Trafficking
2 ADCY, Akt, Alpha catenin, Ap1, CAPZB, CD3, Creb, CSN1S1, 
ERK, estrogen receptor, FYN, GH1, GH2, Histone h3, IDH1, Ige, 
IgG, Insulin, Integrin, Lh, Mapk, p85 (pik3r), PDGF BB, PI3K 
(complex), Pka, PLC, Proinsulin, Ras, SCGN, Shc, TCR, TGM2, 
thyroid hormone receptor, Vegf, VIM
19 35 9 Cardiovascular System 
Development and Function, 
Organismal Development, 
Nervous System Development 
and Function
3 5-hydroxytryptophan, ACOT2, ADRM1, BMP2, CD33, CLPP, 
CRYM, DEFA1 (includes others), DPP7, DUSP9, FBXO32, FRMD6, 
G protein alpha, GDI1, GNL2, GSTM2, Il15r, IL18RAP, Jnk, LPHN2, 
METTL3, MGST3, NFkB (complex), P38 MAPK, PFKFB2, PI3K 
(complex), PIM3, Pkc(s), STK10, TLR6, TLR2/TLR4, TNFRSF17, 
TXNDC9, UBC, ZNF266






Top Diseases and Functions
1 14-3-3, ADCY, AKR1B1, Alpha catenin, Ap1, CAPZB, COL6A2, 
cytochrome C, DBI, ERK1/2, estrogen receptor, F10, GH1, GH2, 
GLO1, GNAO1, GPX4, Growth hormone, IDH1, Igfbp, IGFBP6, 
Insulin, Lh, Mapk, Pka, Pkc(s), PLC, PRL, Proinsulin, SCGN, 
STAT5a/b, Tgf beta, thyroid hormone receptor, TPH2, VIM
36 35 16 Cardiovascular System 
Development and Function, 
Organismal Development, 
Cancer
2 ACOT2, BCLAF1, CBLL1, CDC37, CDK11A/CDK11B, CKS2, 
CKS1B, COX6B1, COX6C, CRYM, DAPK1, DPP7, ELK3, EMD, 
ERH, ERN1, GABARAPL2, GCDH, HSPE1, LUC7L2, METTL3, 
MT-CO2, NCOA5, NDUFS8, PHB, PRDX3, PYGL, RPGRIP1L, 
TAGLN3, TUT1, TXNDC9, UBC, USP10, WTAP, ZNF266
22 35 10 Cell Cycle, DNA Replication, 
Recombination, and Repair, 
Embryonic Development
3 Akt, Alp, ATP5B, CD3, Creb, CTSW, ERK, FAM160B1, FMO3, 
GDI1, GGT5, GSTM2, GZMH, Histone h3, HMCN1, HSP90B1, 
HSPB8, IgG, IL15, IL12 (complex), Il15r, Immunoglobulin, Jnk, 
KRT16, NAGA, NFkB (complex), OGN, P38 MAPK, PI3K 
(complex), PSG1, SYAP1, TGM2, TLR3/4, Vegf, YWHAQ
21 35 10 Cell-To-Cell Signaling and 







Top Diseases and 
Functions
1 ADCY, AKR1B1, Alpha catenin, CAPZB, CD59, COL6A2, 
cytochrome C, DBI, ERK1/2, estrogen receptor, F10, G protein 
alpha, GH1, GH2, GNAO1, GPX4, Growth hormone, IDH1, Igfbp, 
IGFBP6, Insulin, Lh, Nos, PDGF BB, Pka, PLC, PPID, 
PPP2R2A, PRL, Proinsulin, SCGN, STAT5a/b, Tgf beta, TGM2, 
thyroid hormone receptor
39 35 17 Cardiovascular System 
Development and Function, 
Organismal Development, 
Cancer
2 ACOT2, CDC37, CDCA7, CDK4, CLDN3, CLDN5, COX11, 
COX6B1, CRYM, DBI, DPYSL3, ERH, ERP29, GCDH, GSK3B, 
HTR1A, IFIT5, METTL3, MFGE8, MYCL, NCOA5, NDUFS2, 
NDUFS8, PARVA, PRDX3, RALB, RHOQ, RPF2,  SLC9B2, 
TAGLN3, TPH2, TXNDC9, UBC, USP10, ZNF266
30 35 13 Lipid Metabolism, Nucleic 
Acid Metabolism, Small 
Molecule Biochemistry
3 5-hydroxytryptophan, Akt, Alp, Ap1, caspase, CD3, Creb, ERK, 
FFAR2, FYN, GLO1, GSTM2, Histone h3, HSPB1, HSPB7, 
HSPB8, ICAM3, IgG, IL15, IL12 (complex), Jnk, KRT16, Mapk, 
NFkB (complex), OGN, OLFM4, P38 MAPK, PI3K (complex), 
Pkc(s), Ras, Shc, STK10, Ubiquitin, Vegf, YWHAQ
19 35 9 Hereditary Disorder, 
Neurological Disease, 





Top Diseases and Functions
1 ADCY, AKR1B1, Ap1, CAPZB, CD59, cytochrome C, ERK1/2, 
estrogen receptor, F10, G protein alpha, GH1, GH2, GNAO1, 
GPX4, Growth hormone, GSTM2, IDH1, Igfbp, IGFBP6, IL15, 
Insulin, Jnk, Lh, MMP19, Nos, OGN, Pkc(s), PLC, PPID, PRL, 
Proinsulin, SCGN, STAT5a/b, Tgf beta, thyroid hormone 
receptor
41 35 17 Cardiovascular System 
Development and Function, 
Organismal Development, 
Cancer
2 Akt, Alp, Alpha catenin, ATP5B, CD3, CD93, Creb, ERK, 
FFAR2, GLO1, GPR56, Histone h3, HSPB6, HSPB8, ICAM3, 
IgG, IL12 (complex), KRT16, Mapk, NFkB (complex), OLFM4, 
P38 MAPK, PI3, PI3K (complex), Pka, Plc delta, PPP1R16B, 
RNF213, SACS, SLAMF7, STK10, TGM2, TPH2, Vegf, 
YWHAQ
14 35 7 Cell-To-Cell Signaling and 
Interaction, Dermatological 
Diseases and Conditions, 
Developmental Disorder
3 ACOT2, APOE, BMP2, CAMK1, CDC37, CDK6, CFLAR, 
CREB1, CRYM, CSNK2A2, DPP7, ERBB3, GCDH, IFIT5, 
JAK1, LRRK2, MAP3K7, METTL3, NCOA5, NPM1, PDGFRA, 
PRKACA, PRKACB, PSME1, RAD23A, RYK, SNCA, SQSTM1, 
TAB2, TNFRSF1A, TXNDC9, UBC, USP10, WTAP, ZNF266
12 35 6 Post-Translational 




Figure 4 Signal pathway networks in different subtypes of clinically NFPAs. A. NF-NFPA. B. LH-NFPA. C. FSH-NFPA. D. LH/FSH-NFPA.
Zhan et al. BMC Medical Genomics  (2014) 7:69 Page 10 of 18of total nodes) were MS-identified. ERK1/2, PRL, GH1,
LH, MAPK, PKC, PKA, 14-3-3, estrogen receptor, TGF
beta, and insulin play key roles in this network. LH-
network 2 functions in cell cycle, DNA replication, recom-
bination, and repair, embryonic development; and includes
35 nodes (genes; proteins). Among those 35 nodes, 10
DEPs (29% of total nodes) were MS-identified. UBC,
CDC37, and COX6B1 play key roles in this network. LH-
network 3 functions in cell-to-cell signaling and inter-
action, cellular growth and proliferation, hematological
system development and function; and includes 35 nodes
(genes; proteins). Among those 35 nodes, 10 DEPs (29% of
total nodes) were MS-identified. P38 MAPK, Akt, ERK,
NF-kB complex, CD3, IgG, IL15, IL12 complex, Jnk,
VEGF, and TGM2 play key roles in this network.
For FSH-NFPAs, pathway network analysis of 63 DEPs
in FSH-NFPAs identified three statistically significant
pathway networks that involve FSH-NFPA-related DEPs
(Figure 4C). Those nodes in the top-half of Figure 4C cor-
responded to molecules (genes; proteins) that were sum-
marized in the bottom-half of Figure 4C. FSH-network 1functions in cardiovascular system development and func-
tion, organism development, and cancer; and includes 35
nodes (genes; proteins). Among those 35 nodes, 17 DEPs
(49% of total nodes) were MS-identified. ERK1/2, PKA,
PLC, TGF beta, TGM2, LH, GH1, PRL, and insulin play
key roles in this network. FSH-network 2 functions in
lipid metabolism, nucleic acid metabolism, and small-
molecule biochemistry; and includes 35 nodes (genes;
proteins). Among those 35 nodes, 13 DEPs (37% of total
nodes) were MS-identified. UBC, CDC37, and GSK3B
play key roles in this network. FSH-network 3 functions in
hereditary disorder, neurological disease, organismal injury
and abnormalities; and includes 35 nodes (genes; pro-
teins). Among those 35 nodes, 9 DEPs (26% of total
nodes) were MS-identified. P38 MAPK, Akt, ERK, NF-kB
complex, VEGF, Jnk, MAPK, PI3K complex, Creb, PKC,
and HSPB play key roles in this network.
For LH/FSH-NFPAs, pathway network analysis of 55
DEPs in LH/FSH-NFPAs identified three statistically sig-
nificant pathway networks that involve LH/FSH-NFPA-
related DEPs (Figure 4D). Those nodes in the top-half of
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proteins) summarized in the bottom-half of Figure 4D.
LH/FSH-network 1 functions in cardiovascular system
development and function, organism development, and
cancer; and includes 35 nodes (genes; proteins). Among
those 35 nodes, 17 DEPs (49% of total nodes) were MS-
identified. ERK1/2, Jnk, AP1, NOS, AKR1B1, PRL, LH,
PLC, PKC, GH1, STAT5a/b, estrogen receptor, ADCY,
and insulin play key roles in this network. LH/FSH-net-
work 2 functions in cell-to-cell signaling and interaction,
dermatological diseases and conditions, and develop-
ment disorders; and includes 35 nodes (genes; proteins).
Among those 35 nodes, 7 DEPs (20% of total nodes)
were MS-identified. MAPK, TGM2, ERK, NF-kB com-
plex, IL12 complex, VEGF, Creb, Akt, PKA, P38 MAPK,
IgG, and CD3 play key roles in this network. LH/FSH-
network 3 functions in post-translational modification, cell
death and survival, and gene expression; and includes 35
nodes (genes; proteins). Among those 35 nodes, 6 DEPs
(17% of total nodes) were MS-identified. UBC, CDC37,
SOSTM1, PRKACA, and CREB1 play key roles in this
network.
Comprehensive analysis of four sets of pathway net-
works (Figure 4A-D) revealed: (i) The pathway network
(NF-network 2, LH-network 1, FSH-network 1, and LH/
FSH-network 1) was highly similar among NF-, LH-,
FSH-, and LH/FSH-NFPAs, and functions in cancer, car-
diovascular system development and function, organism
development, and nervous system development and
function; and nodes ERK1/2, GH1, LH, insulin, and PRL
play key roles in this common pathway network. However,
they are not the same, and display differences among NF-,
LH-, FSH- and LH/FSH-NFPAs. (ii) The pathway network
(NF-network 1, LH-network 3, and LH/FSH-network 2) is
very similar among NF-, LH-, and LH/FSH-NFPAs, and
functions in cell-to-cell signaling and interaction, hema-
tological system development and function, immune cell
tracfficking, cell growth and proliferation, dermatological
diseases and conditions, and developmental disorder;
network FSH-network 3 is very similar to the above-
mentioned three networks, and functions in hereditary
disorder, neurological disease, and organism injury and ab-
normalities. (iii) The network NF-network 3, LH-network
2, FSH-network 2, and LH/FSH-network 3 are basically
different, however, they have common nodes UBC and
CDC37, and the other nodes are almost different.
Difference in canonical pathways
Among those DEPs in four NFPA subtypes, pathway
network analysis identified 34 statistically significant ca-
nonical pathways that involve DEPs in NF-NFPAs, 21 in
LH-NFPAs, 28 in FSH-NFPAs, and 18 in LH/FSH-NFPAs.
A comparative analysis of those significant canonical path-
ways was performed among NF-, LH-, FSH-, and LH/FSH-NFPAs (Figure 5). (i) A total of 12 canonical path-
ways was common to four NFPA subtypes, including aryl
hydrocarbon receptor signaling, role of JAK2 in hormone-
like cytokine signaling, growth hormone signaling, TR/
RXR activation, IGF-1 signaling, hematopoiesis from mul-
tipotent stem cells, acyl-CoA hydrolysis, serotonin and
melatonin biosynthesis, extrinsic prothrombin activation
pathway, methylglyoxal degradation III, NRF2-mediated
oxidative stress response, and IL-15 production (Figure 5A).
(ii) Two significant canonical pathways were common to
only three NFPA subtypes (NF-, LH-, and FSH-), including
PI3K/AKT signaling, and aldosterone signaling in epithelial
cells (Figure 5B). (iii) Three significant canonical pathways
were common to only three NFPA subtypes (LH-, FSH-,
and LH/FSH-), including mitochondrial dysfunction, gluta-
thione redox reactions I, and methylglyoxal degradation I
(Figure 5C). (iv) One significant canonical pathway, intrin-
sic prothrombin activation pathway, was common to only
three NFPA subtypes (NF-, LH-, and LH/FSH-) (Figure 5C).
(v) Three significant canonical pathways were common to
only two NFPA subtypes (NF-, and LH-), including
PPARα/RXRα activation, 14-3-3-mediated signaling, and
RhoGDI signaling (Figure 5B and C). (vi) Ten significant
canonical pathways were common to only two NFPA sub-
types (NF-, and FSH-), including ERK/MAPK signaling,
prolactin signaling, CTAL4 signaling in cytotoxic T lym-
phocytes, role of tissue factor in cancer, p70S6K signaling,
synaptic long term depression, Tec kinase signaling, Wnt/
β-catenin signaling, role of NFAT in regulation of the im-
mune response, and Ephrin receptor signaling (Figure 5B
and C). (vii) One significant canonical pathway, oxidative
phosphorylation, was common to only two NFPA subtypes
(LH-, and FSH-) (Figure 5C). (viii) Six significant canonical
pathways were specific to only NF-NFPAs, including
mitotic roles of Polo-like kinase, protein ubiquitination
pathway, xenobiotic metabolism signaling, telomerase sig-
naling, production of nitric oxide and reactive oxygen spe-
cies in macrophages, and ILK signaling (Figure 5B and C).
(ix) One significant canonical pathway, Huntington’s
disease signaling, was specific to only LH/FSH-NFPAs
(Figure 5C).
Differences in disease biological events
Among DEPs in four NFPA subtypes, pathway network
analysis identified 77 statistically significant disease bio-
logical events that involve in NF-NFPAs, 76 in LH-
NFPAs, 76 in FSH-NFPAs, and 79 in LH/FSH-NFPAs. A
comparative analysis of those significant disease biological
events was performed among NF-, LH-, FSH-, and LH/
FSH-NFPAs (Additional file 1: Figure S1). (i) A total of 70
disease biological functional events were common to
four NFPA subtypes (NF-, LH-, FSH-, and LH/FSH-)
(Additional file 1: Figure S1A-E), including cancer, deve-
lopment and function of cellular, tissue, and multiple organ
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Figure 5 Canonical pathways that are common and specific to different subtypes of clinically NFPAs (Panels A, B, and C). The blue bar
means NF-NFPA. The light blue bar means LH-NFPA. The green bar means FSH-NFPA. The dark bar means LH/FSH-NFPA.
Zhan et al. BMC Medical Genomics  (2014) 7:69 Page 12 of 18systems, morphology of cell, tissue, organ, and tumor, mul-
tiple diseases and disorders including inflammatory and
neurological diseases, inflammatory and immune re-
sponses, cell-to-cell signaling and interaction, cell death
and survival, cellular movement, cellular growth and
proliferation, protein synthesis, lipid metabolism, mo-
lecular transport, cell cycle, carbohydrate metabolism,
energy production, vitamin and mineral metabolism,
nucleic acid metabolism, DNA replication recombi-
nation and repair, amino acid metabolism, drug meta-
bolism, post-translational modification, and behaviors,
etc. (ii) Some disease biological events were not common
to all NFPA subtypes (Additional file 1: Figure S1F),including protein degradation, protein folding, protein
trafficking, and free radical scavenging, etc.
Difference in biological toxicity events
Among DEPs in four NFPA subtypes, pathway network
analysis identified 21 statistically significant biological
toxicity events that involve DEPs in NF-NFPAs, 12 in LH-
NFPAs, 14 in FSH-NFPAs, and 17 in LH/FSH-NFPAs. A
comparative analysis of those significant biological toxicity
events was performed among NF-, LH-, FSH-, and LH/
FSH-NFPAs (Additional file 1: Figure S2). (i) Ten bio-
logical toxicity events were common to four NFPA sub-
types (NF-, LH-, FSH-, and LH/FSH-), including cardiac
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nephritis, cardiac pulmonary embolism, cardiac stenosis,
increased levels of bilirubin, kidney failure, increased
levels of potassium, and glutathione depletion in liver.
(ii) Two biological toxicity events were common to only
three NFPA subtypes (NF-, FSH-, and LH/FSH-), inclu-
ding increased levels of hematocrit, and increased levels of
red blood cells. (iii) Two biological toxicity events were
common to only two NFPA subtypes (NF-, and LH/FSH-),
including cardiac infraction, and cardiac necrosis/cell
death. (iv) One biological toxicity event, liver hyperplasia/
hyperproliferation, was common to only two NFPA sub-
types (NF-, and LH-). (v) Two biological toxicity events
were common to only two NFPA subtypes (NF-, and
FSH-), including renal necrosis/cell death, and glomerular
injury. (vi) Four biological toxicity events were specific to
NF-NFPAs, including cardiac fibrosis, cardiac inflamma-
tion, cardiac arteriopathy, and liver cirrhosis. (vii) Three
biological toxicity events were specific to LH/FSH-NFPAs,
including heart failure, liver necrosis/cell death, and liver
damage.
Discussion
Reliability of DEP data is the most-important aspect of
2DGE-based comparative proteomics and for pathway
network analysis. In order to achieve reliable DEP data
of each NFPA subtype relative to controls, four strategies
were applied: (a) spatial and quantitative reproducibility
and linear dynamic range of 2DGE analysis systems were
optimized and evaluated carefully [32,33]. An appropri-
ate amount (70 μg) of protein for each 2DGE gel was
used, and a 3-fold “cut-off” with statistical significance
(p < 0.05) was used to determine a DEP. (b) For bio-
logical reproducibility, eight tissue samples for controls
and three tissue samples for each NFPA subtype were
used; and for technique reproducibility, each biological
sample was analyzed with 2DGE for 3–5 times. Thus, a
total of 30 gel images for controls and 9 gel images for
each NFPA subtype was used to detect the DEPs with
3-fold cut-off value (p < 0.05) between each NFPA sub-
type relative to controls (see Figure 2). (c) proteomic
heterogeneity of those eight controls was analyzed [34]
and used to assist in the determination of DEPs for each
NFPA subtype. (d) DEP data were correlated with compara-
tive transcriptomics data, and validated with reverse tran-
scriptase real-time polymerase chain reaction (RT-PCR)
[15,35] to validate the DEP data.
In our long-term NFPA proteomics program, we de-
monstrated DEP profile between NFPAs and controls
[15,35], including 50 DEPs (21 up-regulated and 29
down-regulated) contained in 72 2D gel-spots. Those
DEPs also correlated with differentially expressed genes
(DEGs; n = 284) from transcriptomics analysis, and were
validated with RT-PCR [15,35]. Moreover, pathway networkanalysis of those 50 DEPs [15,35], 111 protein mapping
data [11], and 17 nitroproteins [17-19] revealed four im-
portant signal pathway networks, including mitochondrial
dysfunction, oxidative stress, cell-cycle dysregulation, and
MAPK-signaling system abnormality [23]. However, these
proteomic studies [15,35] and pathway network analysis
[23] did not consider the NFPA heterogeneity, which is an
important clinical problem with NFPAs. The differential
expressions (NF-, LH-, FSH-, and LH/FSH-positive) of LH
and FSH in NFPAs are the common NFPA subtypes.
The present study, for the first time, revealed pro-
teome heterogeneity of four NFPA subtypes (NF-, LH-,
FSH-, and LH/FSH-positive). A set of DEP and signaling
pathway network data was achieved among four NFPA
subtypes. A comprehensive analysis of those compli-
cated DEP data, pathway networks, canonical pathways,
disease biological events, and biological toxicity events
revealed several signaling pathway systems that were
common and specific to different NFPA subtypes and
functioned in an NFPA, including MAPK-signaling ab-
normality, oxidative stress, mitochondrial dysfunction,
and cell-cycle dysregulation.
MAPK-signaling abnormality
This common signaling pathway network abnormality
occurs among four NFPA subtypes. The biological sig-
nificance of MAPK-signaling abnormality in a pituitary
adenoma has been described [23]. MAPK signaling
pathway network involves stimulus (mitogens, cytokines,
growth factors, and stress, etc.), G-protein (Cdc42, Ras,
Rac, and Rho), MAPKKK (Raf, Tpl2, MEKK, MLK, TAK,
ASK, and TAO), MAPKK (MEK), MAPK (ERK, JNK,
and P38), and responses (proliferation, differentiation,
apoptosis, and migration). ERKs, JNKs, and p38-MAPKs
are the three main MAPK subfamilies. ERK 1/2 is acti-
vated by MEK1/2, which is activated by Raf, Ras, and
growth factors or mitogens; Raf activity, as the main
effecter of Ras, is suppressed by cyclic AMP-dependent
kinase (PKA) in a normal cell. JNKs are activated by
MEK4/7, and p38-MAPKs are activated by MEK3/4/6. The
upstream signal of MEK3/4/6/7 is from Rac, Rho, cdc42,
cytokines, or stresses. NF-κB, TNFα, and interleukin-1
regulate this pathway system. The details of MAPK sig-
naling pathways in cancer were reviewed [36-38]. MAPK
pathways are emerging as potential therapeutic targets for
cancer, and development of inhibitors of MAPK pathways
is important for cancer therapy. Pathway analysis of DEPs
among four NFPA subtypes demonstrated that ERK1/2,
ERK, MAPK, GH1, Ras, and NF-κB were the key nodes in
their pathway networks (Figure 4A-D); and the role of
JAK2 in hormone-like cytokine signaling, growth hor-
mone signaling, and ERK/MAPK signaling were signaling
pathway networks in adenomas. Even though MAPK-
signaling abnormalities are a common pathway system
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system is very complicated and includes multiple compo-
nents, and some differences are present in the MAPK sig-
naling network system among four NFPA subtypes. For
example, networks that involve the MAPK-signaling
system (Figure 4) are not the same among four NFPA
subtypes; and ERK/MAPK signaling of the MAPK-
signaling system is statistically significant in only NF- and
FSH-NFPAs (Figure 5B).
Oxidative stress (OS)
OS is a common signaling pathway system among four
NFPA subtypes. The biological significance of oxidative
stress in pituitary adenomas has been described in detail
[23]. Many studies indicated the presence of nitric oxide
synthase (NOS) in the human and rat pituitaries [39-43],
and the increased NOS activities and its increased mRNA
have been found in pituitary adenomas relative to controls
[43,44]. Nitric oxide (NO) is involved in the hypothalamic-
pituitary-adrenocortical axis [45]. NO activates release of
luteinizing hormone-releasing hormone (LHRH) and
follicle-stimulating hormone-releasing hormone (FSHRH)
from the hypothalamus, and of LH and FSH from the pitu-
itary [46-48], stimulates or inhibits the secretion of PRL
[49], regulates growth hormone (GH) secretion in the nor-
mal human pituitary and in acromegaly [50,51], and mo-
dulates GH secretion in a dose-dependent manner in GH
adenomatous cells from human pituitary adenomas [52].
Our pathway analysis of DEPs clearly revealed a statistically
significant NRF2-mediated oxidative stress response ca-
nonical pathway common to each NFPA subtype.
However, some differences in the oxidative stress system
were found; for example, oxidative phosphorylation was
common to only LH- and FSH-NFPAs (Figure 5C); and
production of NO and reactive oxygen species in macro-
phages was specific to LH-NFPAs (Figure 5C).
Mitochondrial dysfunction
This common pathway system occurs among LH-, FSH-,
and LH/FSH-NFPAs, except NF-NFPAs (Figure 5C). The
biological significance of mitochondrial dysfunction in hu-
man pituitary adenoma was described [23]. Mitochondrial
dysfunction was confirmed with a mitochondrial morpho-
logical change in a pituitary tumor, including an increased
number of mitochondria, ultrastructurally abnormal mito-
chondria, large mitochondria, mitochondrial swelling, and
characteristic vesicular mitochondria. Anti-mitochondrial
staining showed intense and granular mitochondria, and
electron microscopy showed swollen mitochondria in the
cytoplasm with featured lamellar cristae in the spindle-cell
oncocytoma of the adenohypophysis. Notable differences in
the structure and function of mitochondria appeared be-
tween cancer and normal cells, and included differences in
mtDNA sequence, molecular composition, and metabolicactivity [53,54]. Mitochondria involve multiple metabolic
functions that include oxidative phosphorylation - an
energy-generating process that couples oxidation of respira-
tory substances to ATP synthesis, oxidative decarboxylation
of pyruvate, the tricarboxylic acid cycle, fatty-acid oxidation,
glycolysis, intracellular homeostasis of inorganic ions such
as calcium and phosphate, and intracellular apoptosis [54].
This present study revealed mitochondria-related signaling
pathways, including serotonin and melatonin biosynthesis,
oxidative phosphorylation, energy metabolism, carbohy-
drate metabolism, and oxidative stress, that function in
human pituitary adenoma cells (Figure 5 and Additional file
1: Figure S1C). Mitochondrial DEPs, including NADH-
ubiquinone oxidoreductase 23 kDa and ATP synthase beta
chain, were identified in NFPAs.
Cell-cycle dysregulation
This dysregulation is a common pathway system among
four NFPA subtypes. The biological significance of cell-
cycle dysregulation in human pituitary adenomas was de-
scribed [23] and reviewed [55-58]. The present study
clearly demonstrated cell-cycle network (Figure 4B) and
cell cycle regulation (Additional file 1: Figure S1F) in
NFPAs. DEP data clearly demonstrated that an important
cell-cycle regulator, 14-3-3 protein, was down-regulated
(NF: lost; LH: lost; FSH: 6.4-fold; and LH/FSH: 15.5-fold)
in four NFPA subtypes relative to controls (Table 1). Fur-
thermore, our previous nitroproteomic data demonstrated
that a nitrated proteasome could interfere with functions
of the ubiquitin-proteasome system in cell-cycle regulation
[23]. Also, the present study clearly demonstrated that
ubiquitin C (UBC) was the key node among four NFPA
subtypes (Figure 4) to suggest that oxidative/nitrative
stress might also be involved in cell-cycle dysregulation in
human pituitary adenomas.
In summary, although those pathway systems are com-
mon to four NFPA subtypes, one must note that those
pathway network systems are, in fact, different among four
NFPA subtypes. First, most nodes had different expression
levels among four NFPA subtypes - with strong evidence
of those DEP data in Table 1 and Figure 3. Second, those
pathway networks were not completely the same among
four NFPA subtypes - with evidence in Figures 4 and 5.
Third, the main pituitary hormones, growth hormone and
prolactin, clearly demonstrated multiple isoforms, and
were differentially expressed in four NFPA subtypes rela-
tive to controls (Table 1). Those abnormal expressions of
those pituitary hormones significantly functioned in path-
way systems such as MAPK-signaling system described
above (Figures 4 and 5), and were involved in patho-
physiological processes. Therefore, those DEP profiles
(Table 1 and Figure 3), the functional characteristics of
those DEPs, and variations in signaling pathway systems
(Figures 4 and 5) provide a heterogeneous profile of
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is essential for an in-depth understanding of NFPA-
proteome heterogeneity to accurately clarify basic NFPA
molecular mechanisms and to discoverer biomarkers for
effective diagnosis, therapy, and prognosis to achieve per-
sonalized medicine practice for an NFPA.
Conclusions
The present study used large-scale quantitative proteo-
mics and systems biology strategies to clarify variations
in proteomes and network systems among four NFPA
subtypes and to elucidate NFPA-proteome heterogeneity.
Results demonstrate common and specific DEP profiles
and pathway networks among four NFPA subtypes and
for the first time reveal NFPA-proteome heterogeneity.
Those data provide a starting point to discover effective
biomarkers and effective targets to achieve personalizedTable 2 Clinical information of clinically nonfunctional pituita
Groups Sample ID Sex/Age Clinical information
NF-NFPA T164 M/35 Non-functional, visual l
T217 M/39 Non-functional
T219 M/68 Non-functional, 1.9 × 2
sinus
LH-NFPA T208 F/47 Non-functional, 2 × 2 ×
T204 M/47 Non-functional
T237 F/40 Non-functional, right c
FSH-NFPA T57 F/59 Non-functional, 2 × 3 c
T89 M/62 Non-functional, 2 × 2.3
T77 M/67 Non-functional, 2 × 2.2
LH/FSH-NFPA T65 F/54 Non-functional, 4 × 4 ×
T138 M/60 Non-functional, 2.9 × 3
T185 M/66 Non-functional, 2.8 ×, 2
Control pituitary (Con) C2 M/27 Black, none
C3 F/40 White, Multiple toxic co
(−)
C4 M/45 White, Drowning. Bloo
Blood: HepB (+), HepC
C5 M/36 White, Multiple toxic m
HepB (+), HepC (−), HIV
C7 F/34 Black, Gunshot wound
Blood: HepB (+), HepC
C8 F White, 15 h gunshot w
HepB (−), HepC (−), HIV
C9 M/55 White, 12 h gunshot w
HepB (−), HepC (−), HIV
C10 F/47 White, Smoke inhalatio
present in brain. Early a
HepC (+), HIV (−)
Note: All those hormones (ACTH, LH, FSH, PRL, GH, and TSH) were immunohistoche
stains for ACTH, LH, FSH, PRL, GH, and TSH were negative. LH+ = nonfunctional pitu
FSH+ = nonfunctional pituitary adenoma that expressed follicle-stimulating hormon
both follicle-stimulating hormone and leuteinizing hormone. Adenomas were grade
peptide hormone. NFPA = nonfunctional pituitary adenoma. DNT = do not test.medicine practice for an NFPA. Further experiments
and more biological specimens are needed to investigate
the biological significance of each altered pathway sys-
tem in an NFPA biological system.
Methods
Pituitary adenomas, control tissues, and preparation of
proteins
Differential gel spots that contained DEPs between dif-
ferent NFPA subtypes versus controls were derived from
re-analysis of 2DGE images [15,35] that included eight
whole control pituitary tissues and twelve NFPA tissues,
and each sample had three to five replicate 2DGE im-
ages. Also, DEPs were validated with the proteomic va-
riation data of eight controls [34]. Clinical information
of pituitary adenoma and control tissue samples was col-
lected in Table 2. Collection and management of thosery adenoma and control pituitary samples
Immunohistochemistry
oss, 3 × 3.5 × 4 cm. Partial hypopituitarism Neg.
Neg.
.3 × 2.2 cm, invasion of the right cavernous Neg.
2 cm LH 1-2+
LH 3+
avernous sinus extension LH 2+
m FSH 1+
× 2.3 cm FSH 2+
× 2.4 cm, questionable cavernous sinus FSH 2+
4 cm, cavernous sinus invasion LH 2+, FSH 1+
.1 × 3.5 cm LH 2+, FSH 2+
× 2.4 cm. Bilateral cavernous sinus invasion LH 2-3+, FSH 2-3+
DNT
mpounds. Blood: HepBb (+), HepC (+), HIV DNT
d alcohol = 3.1 g/L; no other drugs detected.
(+), HIV (−)
DNT
aterials. Blood alcohol = 0.5 g/L. Blood:
(−)
DNT
to chest. Blood alcohol = 0.3 g/L; no drugs.
(−), HIV (−)
DNT
ound to head. No drugs or alcohol. Blood:
(−)
DNT
ound to chest. No alcohol or drugs. Blood:
(−)
DNT
n. No drugs or alcohol. Numerous amylacea
utolytic changes to brain. Blood: HepB (−),
DNT
misty-tested in each pituitary adenoma tissue. Neg. = Immunohistochemical
itary adenoma that expressed leuteinizing hormone, or lutropin;
e, or follitropin; FSH+, LH+ = nonfunctional pituitary adenoma that expressed
d blindly by a neuropathologist (from 0–4) for the intensity of staining for each
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Board (IRB) of the University of Tennessee Health Science
Center. The detailed sample collection procedure was
described [35]. Each control pituitary tissue (0.45-0.70 g;
n = 8) and each NFPA tissue (15–75 mg; n = 12) was ho-
mogenized individually, lyophilized, and protein content
was quantified; proteins (70 μg) were used for a 2DGE
analysis. The detailed procedure of protein sample prepa-
ration was described [11].2DGE and 2D gel image analysis
First-dimension, IEF, was carried out on a Mulitphor II
instrument (GE Health) with 70 μg protein sample and
precast IPG strips (pH 3–10 NL; 180 × 3 × 0.5 mm).
After equilibration of IEF-separated proteins, second-
dimension, SDS-PAGE, was carried out with a 12%
PAGE resolving gel (190 × 205 × 1.0 mm) in a vertical
PROTEAN plus Dodeca™ Cell (Bio-Rad) which can
analyze up to 12 gels at a time. 2DGE-separated proteins
were visualized with a modified silver-staining method.
Silver-stained 2DGE gels were digitized and analyzed
with a PDQuest system (Version 7.1.0; Bio-Rad). A
matched analysis set that contained 30 gel images from
8 control pituitary samples, 9 gel images from 3 NF-
NFPA samples, 9 gel images from 3 LH-NFPA samples,
9 gel images from 3 FSH-NFPA samples, and 9 gel im-
ages from 3 LH/FSH-NFPA samples (a control pituitary
as master gel) used to compare each DEP of NF-, LH-,
FSH-, and LH/FSH-NFPAs relative to controls, respec-
tively. Comparative analyses were carried out with the
mean normalized volume between each NFPA subtype
and controls. The “cutoff point” value for a significant
difference of a differential spot was a three-fold differ-
ence. The detailed 2DGE method and 2D gel image ana-
lysis were described [11].MALDI-TOF PMF and LC-ESI-MS/MS analyses
Each 2D gel-spot that contained a DEP was excised. Pro-
tein was subjected to in-gel digestion with trypsin, purifica-
tion of tryptic peptides with a Zip-TipC18 micro-column,
followed by analysis with a Perseptive Biosytems MALDI-
TOF Voyager DE-RP mass spectrometer (Framingham,
MA, USA) and with an LCQDeca mass spectrometer (LC-
ESI-Q-IT) equipped with a standard electrospray source
(ThermoFinnigan, San Jose, CA, USA). For MALDI-TOF
MS, peptide mass fingerprint (PMF) data were gene-
rated; PMF data were used to identify protein with a
search of the UniProt database with search software Pept-
Ident (http://us.expasy.org/tools/peptident.html) and Mas-
cot (http://www.Matrixscience.com). For LC-ESI-Q-IT
MS, tandem mass spectrometry (MS/MS) data were
generated; MS/MS data were used to identify protein with
a search of the UniProt and NCBInr databases with theSEQUEST software. Detailed experimental procedures
were described [11].
Pathway network analysis
The Ingenuity Pathway Analysis (IPA) system was used to
obtain cellular pathways that might be modified by protein
changes identified in these experiments. IPA automatically
generated networks of gene, protein, small-molecule,
drug, and disease associations on the basis of “hand-
curated” data held in a proprietary database. Identifiers
(Swiss-Prot identification number) of DEPs were uploaded
as an Excel spreadsheet file into the Ingenuity software
(Ingenuity Systems, Redwood City, CA, USA). Each hu-
man identification number was mapped to its correspon-
ding molecule in the Ingenuity Pathway Knowledge Base.
Biological functions assigned to each network were ranked
according to significance of that biological function to the
network. Protein networks were algorithmically generated
based on their connectivity and were assigned a score.
The score was used to rank networks according to how
relevant they were to the proteins in the input data set.
The network was presented as a graph that indicated the
molecular relationship between proteins.
Additional file
Additional file 1: Figure S1. Significant disease biological events that
are common and specific to different subtypes of clinically NFPAs. The
blue bar means NF-NFPA. The light blue bar means LH-NFPA. The green
bar means FSH-NFPA. The dark bar means LH/FSH-NFPA. Figure S2.
Significant biological toxicity events that are common and specific to
different subtypes of clinically NFPAs. The blue bar means NF-NFPA. The
light blue bar means LH-NFPA. The green bar means FSH-NFPA. The dark
bar means LH/FSH-NFPA.
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